Select a medication above to begin.
miso
soy (Glycine max)
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- Alzheimer dementia [Insufficient Evidence]
- asthma [Insufficient Evidence]
- BPH [Possibly Ineffective]
- cancer prevention, breast [Possibly Effective]
- cancer prevention, cervical [Insufficient Evidence]
- cancer prevention, colorectal [Possibly Ineffective]
- cancer prevention, endometrial [Insufficient Evidence]
- cancer prevention, gastric [Insufficient Evidence]
- cancer prevention, lung [Insufficient Evidence]
- cancer prevention, thyroid [Insufficient Evidence]
- cardiovascular dz prevention [Insufficient Evidence]
- child growth [Insufficient Evidence]
- CKD [Possibly Effective]
- cognitive function [Insufficient Evidence]
- cognitive impairment [Insufficient Evidence]
- colic [Insufficient Evidence]
- Crohn dz [Insufficient Evidence]
- diabetes mellitus [Possibly Effective]
- diabetic nephropathy [Insufficient Evidence]
- diarrhea [Possibly Effective]
- dyspepsia [Insufficient Evidence]
- exercise-induced muscle soreness [Possibly Ineffective]
- fibromyalgia [Insufficient Evidence]
- galactosemia [Possibly Effective]
- hepatitis C [Insufficient Evidence]
- hot flashes, androgen deprivation tx-assoc. [Insufficient Evidence]
- hot flashes, breast CA-assoc. [Possibly Ineffective]
- HTN [Possibly Effective]
- hyperlipidemia [Possibly Effective]
- IBS [Insufficient Evidence]
- lactose intolerance [Possibly Effective]
- mastalgia [Insufficient Evidence]
- menopausal sx [Possibly Effective]
- menstrual migraine prophylaxis [Insufficient Evidence]
- metabolic syndrome [Possibly Effective]
- muscle strength [Possibly Effective]
- neonatal jaundice prevention [Insufficient Evidence]
- nonalcoholic fatty liver dz [Insufficient Evidence]
- obesity [Insufficient Evidence]
- osteoarthritis [Insufficient Evidence]
- osteoporosis [Possibly Effective]
- overall mortality [Insufficient Evidence]
- polycystic ovary syndrome [Insufficient Evidence]
- postmenopausal conditions [Insufficient Evidence]
- premenstrual syndrome [Insufficient Evidence]
- preterm labor prevention [Insufficient Evidence]
- prostate CA [Insufficient Evidence]
- rheumatoid arthritis [Insufficient Evidence]
- sarcopenia [Insufficient Evidence]
- stroke [Insufficient Evidence]
- vaginal atrophy [Insufficient Evidence]
- wrinkled skin [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Special Note
- [formulation clarification]
- Info: may incl. whole soy foods, isolated soy protein, soy fiber or soy extracts; soy products contain isoflavone phytoestrogens, such as genistein and daidzein
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
asthma
- [Insufficient Evidence]
- Dose: 250 mcg genistein PO for every 1000 kcal consumed
cognitive function
- [Insufficient Evidence]
- Dose: 60-110 mg soy isoflavones PO qd
diabetes mellitus
- [Possibly Effective]
- Dose: 300 mg Touchi extract PO tid; Alt: 40-161 mg soy isoflavones PO qd; 0.3 g/kg/day soy protein PO in divided doses starting 24-28 wk gestation
diarrhea, peds pts
- [Possibly Effective]
- Dose: soy fiber-fortified formula PO 3-8x/day; Info: individualize dose; soy protein content 1.8-2 g/dL of soy formula
hepatitis C
- [Insufficient Evidence]
- Dose: 32 g soy protein PO qd
HTN
- [Possibly Effective]
- Dose: 18-40 g soy protein PO qd; Alt: 4.5 g black soy peptide PO qd
hyperlipidemia
- [Possibly Effective]
- Dose: 20-50 g soy protein PO qd
IBS
- [Insufficient Evidence]
- Dose: 40 mg soy isoflavones PO qd
CKD
- [Possibly Effective]
- Dose: 700-800 mg/kg/day soy protein PO in divided doses; Max: 800 mg/kg/day
mastalgia
- [Insufficient Evidence]
- Dose: 17 g soy milk PO bid
menopausal sx
- [Possibly Effective]
- Dose: 34-200 mg/day soy isoflavones PO divided qd-tid
menstrual migraine prophylaxis
- [Insufficient Evidence]
- Dose: 60 mg soy isoflavones PO qd; Info: used w/ dong quai and black cohosh
metabolic syndrome
- [Possibly Effective]
- Dose: 30 g soy nut or soy protein PO qd; Info: dietary replacement of red meat
muscle strength
- [Possibly Effective]
- Dose: 1.2-1.5 g/kg/day soy protein PO in divided doses; Alt: 25 g soy protein PO qd
neonatal jaundice prevention
- [Insufficient Evidence]
- Dose: 0.3 g/kg/day soy protein PO in divided doses; Start: 24-28 wk gestation
obesity
- [Insufficient Evidence]
- Dose: 4.5 g black soy peptide PO qd; Alt: 100 g soy fiber PO qd; 52 g soy protein PO bid
osteoarthritis
- [Insufficient Evidence]
- Dose: 40 g soy protein PO qd
osteoporosis
- [Possibly Effective]
- Dose: 50-90 mg soy isoflavones PO qd
overall mortality
- [Insufficient Evidence]
- Dose: 60 g soy PO qd
polycystic ovary syndrome
- [Insufficient Evidence]
- Dose: 50 mg soy isoflavones PO qd
premenstrual syndrome
- [Insufficient Evidence]
- Dose: 68 mg soy isoflavones PO qd
prostate CA, tx or prevention
- [Insufficient Evidence]
- Dose: 8 oz soy milk PO tid; Alt: 107-117 mg soy isoflavones PO qd
sarcopenia
- [Insufficient Evidence]
- Dose: 16 g soy protein PO qd
vaginal atrophy
- [Insufficient Evidence]
- Dose: 1 g PV qd; Info: 4% isoflavone vaginal gel
wrinkled skin
- [Insufficient Evidence]
- Dose: 40 mg soy isoflavones PO qd; Alt: apply soy based moisturizer topically bid
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.